



**Figure S2**

**Fig S2: Statin use trends towards longer PFS in one of the two venetoclax clinical trials.**

VEN = subjects with at least one dose of venetoclax and without use of statin; VEN + Statin = subjects with at least one dose of venetoclax and with use of statin.

**A.** Trial M15-538 is an ongoing phase II trial of venetoclax/dexamethasone/carfilzomib; the data cutoff date for this PFS analysis was 30 May, 2021.

**B.** Trial M12-901 is a completed phase 1b trial of venetoclax/dexamethasone/bortezomib.